Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03548285 · OUTCOME

Percentage of Participants With Locoregional Failure Following SABR With Death as a Competing Risk

Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer · Source last updated 2025-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
2 years

What was measured

Specifically, the 2-year cumulative risk of biopsy-proven recurrence anywhere in the larynx or neck following SABR. Recurrence in this context includes biopsy-proven cancer anywhere in the supraglottic, glottic, or subglottic larynx, as well as any malignant lymph node in the cervical or supraclavicular lymph nodes.

Groups in this outcome

All Patients

All patients on the clinical trial.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients25

Reported measurements

2 Years
Values in Percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients8Not reported324Not reported
1 Year
Values in Percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients4Not reported0.820Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        24
        value
        8
    title
    2 Years
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.8
        upper Limit
        20
        value
        4
    title
    1 Year
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Specifically, the 2-year cumulative risk of biopsy-proven recurrence anywhere in the larynx or neck following SABR. Recurrence in this context includes biopsy-proven cancer anywhere in the supraglottic, glottic, or subglottic larynx, as well as any malignant lymph node in the cervical or supraclavicular lymph nodes.
dispersion Type
90% Confidence Interval
groups
  1. description
    All patients on the clinical trial.
    id
    OG000
    title
    All Patients
param Type
NUMBER
reporting Status
POSTED
time Frame
2 years
title
Percentage of Participants With Locoregional Failure Following SABR With Death as a Competing Risk
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice